Physician profile
Ali Mojaverian
NPI 1205829843
$5,873.98
in general payments reported to CMS, 2019-2025
34 companies · $1,480 in 2025
The $1,480 reported for 2025 was more than what 83% of Critical Care Medicine (Internal Medicine) providers received nationally (typical 2025 total: $189).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $747 · 2020: $855 · 2021: $734 · 2022: $991 · 2023: $306 · 2024: $760 · 2025: $1,480.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,546.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,546.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,236.50 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Boston Scientific Corporation | $1,080.65 | 2021-2022 | |
| Veran Medical Technologies, INC. | $855.01 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $505.35 | 2019-2025 | Tezspire, Fasenra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $425.83 | 2019-2025 | Ofev, Jascayd |
| Viatris Specialty LLC | $280.19 | 2025 | Yupelri |
| Inspire Medical Systems, INC. | $257.13 | 2022-2023 | Inspire |
| Electromed, INC. | $123.48 | 2023-2025 | Smartvest |
| Grifols USA, LLC | $123.07 | 2019-2025 | Prolastin-C Liquid |
| Regeneron Healthcare Solutions, INC. | $114.00 | 2019-2024 | Dupixent |
| Intuitive Surgical, INC. | $104.47 | 2023 | Da Vinci Surgical System |
| Philips North America LLC | $102.17 | 2019-2025 | (Ak6) Vest Therapy, Vest Therapy Und |
| Verona Pharma, INC. | $96.26 | 2025 | Ohtuvayre |
| Jazz Pharmaceuticals INC. | $79.30 | 2019-2025 | |
| United Therapeutics Corporation | $52.86 | 2021 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $34.75 | 2025 | Zepbound |
| Novartis Pharmaceuticals Corporation | $33.50 | 2019 | |
| Insmed, INC. | $30.62 | 2022-2023 | Arikayce |
| 3b Medical, INC. | $30.56 | 2025 | Luna |
| E.R. Squibb & Sons, L.L.C. | $28.99 | 2022 | |
| Ani Pharmaceuticals, INC. | $27.54 | 2025 | Purified Cortrophin Gel |
| Melinta Therapeutics, LLC | $25.22 | 2019 | |
| Avadel Cns Pharmaceuticals, LLC | $23.05 | 2025 | Lumryz |
| Mallinckrodt Hospital Products INC. | $22.27 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $21.06 | 2019 | |
| Itamar Medical INC | $20.89 | 2025 | Watchpatone |
| Genentech USA, INC. | $19.37 | 2019 | |
| Janssen Pharmaceuticals, INC | $19.19 | 2021 | |
| Merck Sharp & Dohme LLC | $18.43 | 2019 | |
| Sunovion Pharmaceuticals INC. | $17.34 | 2019 | |
| Pulmonx Corporation | $17.24 | 2024 | Zephyr Endobronchial Valve, Chartis Catheter, Pulmonx Chartis Tablet Console |
| Shire North American Group INC | $16.51 | 2019 | |
| Abiomed | $16.36 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $14.82 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ali Mojaverian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.